Hafslund Nycomed AS, Molecular Biosystems Inc.'s Europeanlicensee, has filed a new drug application (NDA) for Albunex inthe United Kingdom as part of the European Communitymultistate approval procedure. Albunex, a cardiac ultrasoundimaging agent, has already been recommended for marketing bythe U.S. FDA., and is also under review in Japan. MolecularBiosystems (NYSE:MB) of San Diego develops and manufacturescontrast agents for medical imaging, including ultrasound,magnetic resonance and computerized tomography.

(c) 1997 American Health Consultants. All rights reserved.

No Comments